Orthofix Medical (NASDAQ:OFIX) Announces Earnings Results

Orthofix Medical (NASDAQ:OFIX) posted its quarterly earnings data on Wednesday. The medical device company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02, FiscalAI reports. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. The firm had revenue of $210.93 million during the quarter, compared to the consensus estimate of $209.28 million.

Here are the key takeaways from Orthofix Medical’s conference call:

• Q2 net sales grew 5% on a pro forma constant-currency basis, led by 10% growth in global spine fixation and 11% growth in global limb reconstruction. Biologics stabilized to approximately flat year over year after significant declines in 2025.
• CMS restored Medicare reimbursement for bone-growth stimulators retroactive to May 18, providing an estimated $12 million benefit and improving visibility for Therapeutic Solutions in the second half. The company also launched the redesigned AccelStim 2.0 device.
• Orthofix raised its 2026 outlook to $845 million-$855 million in net sales and $95 million-$98 million in adjusted EBITDA. The increase includes reimbursement recovery and approximately $15 million of European distributor inventory purchases tied to MDR certification work, with most of that revenue expected in Q4.
• Smaller U.S. spine distributors, representing roughly 20% of spine sales, continue to underperform due primarily to weak asset utilization and channel productivity. Management expects the softness to persist through year-end and is considering consolidating or exiting weaker relationships, which implies only about 2%-3% core growth in the second half excluding the European order.
• The company is investing in clinical evidence for biologics products and pursuing a potential diabetic-foot-ulcer indication for its limb-reconstruction technologies. Orthofix also completed initial VIRATA minimally invasive spine cases and expects a full market launch late in the fourth quarter.

Orthofix Medical Price Performance

Shares of OFIX traded down $1.75 during midday trading on Wednesday, hitting $10.45. The company’s stock had a trading volume of 747,326 shares, compared to its average volume of 333,265. Orthofix Medical has a one year low of $8.85 and a one year high of $16.99. The company’s fifty day simple moving average is $10.46 and its two-hundred day simple moving average is $11.77. The company has a quick ratio of 1.76, a current ratio of 2.87 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $422.19 million, a price-to-earnings ratio of -6.90 and a beta of 0.68.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on OFIX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research report on Friday, July 17th. Wall Street Zen cut Orthofix Medical from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Barrington Research upped their target price on Orthofix Medical from $15.00 to $17.00 and gave the company an “outperform” rating in a research report on Monday, July 6th. Canaccord Genuity Group decreased their price target on Orthofix Medical from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 21st. Finally, TD Cowen reaffirmed a “hold” rating on shares of Orthofix Medical in a research note on Thursday, May 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $16.00.

Insider Buying and Selling

In other Orthofix Medical news, Director John B. Henneman III acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was acquired at an average cost of $12.26 per share, for a total transaction of $61,300.00. Following the transaction, the director directly owned 90,809 shares in the company, valued at $1,113,318.34. This represents a 5.83% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Aviva Mcpherron sold 3,670 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.38, for a total value of $34,424.60. Following the completion of the sale, the insider directly owned 66,330 shares in the company, valued at $622,175.40. This trade represents a 5.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Orthofix Medical

A number of institutional investors have recently added to or reduced their stakes in OFIX. Rubric Capital Management LP lifted its stake in Orthofix Medical by 0.7% in the 2nd quarter. Rubric Capital Management LP now owns 3,721,715 shares of the medical device company’s stock valued at $41,497,000 after purchasing an additional 26,769 shares during the last quarter. Paradigm Capital Management Inc. NY increased its holdings in shares of Orthofix Medical by 34.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock worth $37,248,000 after buying an additional 858,900 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Orthofix Medical by 86.6% during the third quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock worth $21,605,000 after buying an additional 684,850 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Orthofix Medical by 6.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,142,545 shares of the medical device company’s stock valued at $16,726,000 after acquiring an additional 68,596 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Orthofix Medical by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 947,189 shares of the medical device company’s stock valued at $14,362,000 after acquiring an additional 5,869 shares during the last quarter. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.